Monoclonal antibody · Antagonist of monomethyl auristatin E (MMAE) · developed by Generate Biomedicines
GB-4362 is a monoclonal antibody that binds and neutralizes unconjugated monomethyl auristatin E (MMAE), the cytotoxic payload released from some antibody-drug conjugates into the circulation. It does not bind MMAE within an intact antibody-drug conjugate. It is studied in urothelial cancer in combination with an MMAE-containing antibody-drug conjugate.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07484022 | Phase 1 | Advanced Urothelial Cancer | Recruiting | GENB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Urothelial CancerMetastatic Urothelial Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the GENB page.
See GENB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GENB catalysts and pipeline →